ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Dasatinib is a second-generation ABL tyrosine kinase inhibitor (TKI), approved for the treatment of chronic myeloid leukemia (CML) and BCR-ABL-positive acute lymphoblastic leukemia (ALL).